Form 4: Tango Therapeutics Director Equity Grant
Director Equity Compensation Disclosure
Director Sung Lee received an equity grant of restricted stock units and stock options from Tango Therapeutics.
Summary
- Director Sung Lee was granted 570 restricted stock units (RSUs) on June 5, 2026.
- The RSUs vest on the earlier of June 5, 2027, or the date of the next annual stockholders meeting.
- Director Lee was also granted 3,570 stock options with an exercise price of $20.22.
- The stock options vest in 12 equal monthly installments starting July 5, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Dilutive impact of new equity grants on existing shareholders.
Risks
- Vesting is subject to the director's continuous service with the company.
Future Outlook
The equity grants are subject to continuous service requirements, incentivizing the director's ongoing commitment to the company's strategic goals.
Industry Context
StockSavvy.ai notes that standard director compensation packages in the biotechnology sector frequently utilize a mix of RSUs and stock options to ensure long-term retention and alignment with clinical development milestones.
Comparison to Industry Standards
- The use of annual equity grants for board members is consistent with standard corporate governance practices for NASDAQ-listed biotech firms.
- Vesting schedules of one year for director equity are common among mid-cap pharmaceutical companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director Sung Lee authorized Julie Fogarty and Matthew Gall to sign and file SEC documents on his behalf. | 2026-06-07 | Standard administrative procedure to ensure timely regulatory compliance. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of stock options beginning July 5, 2026.
- Vesting of RSUs on June 5, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 2026-06-05 | Transaction date for RSU and stock option grants. |
| 2026-06-07 | Execution date of the Power of Attorney. |
| 2026-06-08 | Filing date of the Form 4. |
| 2026-07-05 | First vesting date for stock options. |
| 2027-06-05 | Vesting date for restricted stock units. |
| 2036-06-05 | Expiration date for stock options. |
Keywords
Tango Therapeutics, TNGX, Form 4, Director Compensation, Equity Grant, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.